CMND and NTLX Related Headlines
Go Back- Clearmind patent application for dyskinesia treatment published in Japan
- Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder
- NeuroThera files 3 U.S. patents on LSD, ketamine, ibogaine combos
- SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations
- Clearmind files 3 U.S. patent applications on LSD, ketamine, ibogaine
- Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations
- Clearmind Medicine files Hong Kong patent for depression therapy combo
- Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy
CMND and NTLX Related Press Releases
Go Back- Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder
- SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations
- Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations
- Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy
